Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease.
about
Perspectives on systems biology applications in diabetic kidney diseaseBiomarkers in nephrology: Core Curriculum 2013Proteomics and metabolomics in renal transplantation-quo vadis?Proteomic candidate biomarkers of drug-induced nephrotoxicity in the ratUrinary collagen fragments are significantly altered in diabetes: a link to pathophysiologyPeptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkersA distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapyUrinary proteomics to support diagnosis of strokeProteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate ProductsSeminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced diseaseMulticentric validation of proteomic biomarkers in urine specific for diabetic nephropathyNaturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitisClassical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications.Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney diseaseProteomics of vitreous humor of patients with exudative age-related macular degenerationUrinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuriaUrine collection and processing for protein biomarker discovery and quantification.Addressing the challenge of defining valid proteomic biomarkers and classifiers.Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology.Identification of urinary peptide biomarkers associated with rheumatoid arthritis.Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population.Evaluation of urinary protein precipitation protocols for the multidisciplinary approach to the study of chronic pelvic pain research networkComprehensive human urine standards for comparability and standardization in clinical proteome analysis.CKD273, a new proteomics classifier assessing CKD and its prognosisDiagnosis and Prediction of CKD Progression by Assessment of Urinary PeptidesIdentification of Symptomatic Fetuses Infected with Cytomegalovirus Using Amniotic Fluid Peptide BiomarkersUrine proteomics in the diagnosis of stable angina.Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction.Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis.Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment.Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease.Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population.Urinary proteomics for early diagnosis in diabetic nephropathy.Identification of ageing-associated naturally occurring peptides in human urineApplication of biomarkers in the development of drugs intended for the treatment of osteoarthritisProteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentreAcute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study.
P2860
Q26823206-1A803587-1762-4967-AFE5-56DB43D19D10Q26861451-D14CAB34-43AA-44E9-B85A-CC600985FECCQ27024418-2268D09D-CCFE-44A6-80AB-B9BED0D638E6Q27305109-57960666-6CEF-4EFA-B85F-323E9F8C3786Q28475613-7C55B10A-FCA3-4015-AF1B-A88BF73C6187Q28477629-B69FB9B1-DEA3-4A79-8E69-77FA171AF614Q28478586-0E3AF515-2085-4B0A-A9E6-5579E09E9A33Q28483776-34F1F500-24DA-4F76-9E8C-77A63E5B0CFAQ28533986-4C412888-F2C0-4B5B-B78F-3EFB09B48105Q28534235-AC04D400-1AFA-4709-81E7-506BB9E73CABQ28748796-91A4C834-A03E-4A23-BC3D-E8B85303B9F1Q30430034-7BFE36B8-0CEF-478D-B1BF-FCB1BCE7C941Q30434677-F7254ADD-B6AA-45FE-BB7E-96D23AB47012Q31148183-89D8549D-B8B6-4267-B145-87397640D2AAQ33436829-5A1CE034-430C-45A6-9552-B5198C9AEEBDQ33591146-2248D3E0-177D-4861-A50E-1CDCF1D02969Q33610106-0C0BE2AF-21CE-4802-A332-FC7C67DC24F9Q33735287-12A0B8C2-B700-47AB-94B1-318FD1CBBEA7Q33780855-7F41AA59-965B-4A18-B35B-6EC3EE075B18Q33786157-22592783-029D-47DE-ACD7-6BBCB06A38AFQ33985444-0846553D-DE6C-4E32-A3CD-7C6F8A244D1AQ34039254-E4AD8E06-830A-439E-A311-01FF848C778FQ34075303-1894B8F7-3CA8-43DA-917B-95DBB78AA1EFQ34140378-693E825E-EC37-4A50-AF0C-7DDFDB745E43Q34413086-6DC3C8AB-6FB3-49AB-B2C9-21895BA679EAQ34725022-7987066E-5B41-40A5-B5DB-5C18AC1FF719Q34729912-47EAAB86-038B-43BD-8DCE-DB61FCD34B3CQ35903097-5736708C-8B44-4E3F-9004-D5A6715B6C81Q35903895-49F9F15E-1B06-495D-9280-BCFFA7682BEFQ35994430-AF92CBCD-8249-4F50-BADE-A6FE023120E1Q36053833-A9BA03AF-6E39-46FF-ABAE-C8D01DF35DAAQ36089848-406474DF-B727-4A14-9561-0BDEB35B14A4Q36171255-F178DAB7-6D8C-4788-A042-DF4A15AF06D5Q36214366-2088A4D0-6AB1-4EAD-8529-570038842019Q36222011-94E35DC3-E445-4BF0-BD08-432997DDB394Q36410737-F5D61F41-639C-4D74-B0C7-EE15817044ADQ36544030-0C170170-7E65-4D40-879F-F24641BB14AAQ36598469-36DF21DE-F0B9-44E2-86EE-AFE1ED037007Q36670632-FB89D27E-19B0-4376-8282-941EDD31FC17Q36942126-B8C04D53-C50B-440B-BD37-7940ACA036AB
P2860
Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Quantitative urinary proteome ...... ion in chronic kidney disease.
@en
Quantitative urinary proteome ...... ion in chronic kidney disease.
@nl
type
label
Quantitative urinary proteome ...... ion in chronic kidney disease.
@en
Quantitative urinary proteome ...... ion in chronic kidney disease.
@nl
prefLabel
Quantitative urinary proteome ...... ion in chronic kidney disease.
@en
Quantitative urinary proteome ...... ion in chronic kidney disease.
@nl
P2093
P356
P1476
Quantitative urinary proteome ...... ion in chronic kidney disease.
@en
P2093
Christian Delles
Eric Schiffer
Gerhard Schumann
Justyna Jantos-Siwy
Kasper Rossing
Korbinian Brand
P304
P356
10.1021/PR800401M
P577
2009-01-01T00:00:00Z